|
| Press Releases |
|
 |
|
| Thursday, June 29, 2023 |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
| Wednesday, September 16, 2020 |
|
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
| Wednesday, May 20, 2020 |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
| Tuesday, March 17, 2020 |
|
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
| 新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社（NYSE American: NNVC） （以下「当社」）は、COVID-19を引き起こす現在の新型コロナウイルス（SARS-CoV-2）の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
|
NanoViricides公司冠狀病毒藥物開發更新 |
| NanoViricides公司（美國紐約證券交易所交易代碼NNVC）（公司）是基於新型納米藥學平台（公司）開發高效抗病毒治療方法的領先公司，目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發，現提供其工作相關更新。 more info >> |
|
|
NanoViricides公司冠状病毒药物开发更新 |
| NanoViricides公司（美国纽约证券交易所交易代码 NNVC）（公司）是基于新型纳米药学平台（公司）开发高效抗病毒治疗方法的领先公司，目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发，现提供其工作相关更新。 more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
国资护航+技术壁垒+优质保荐 华芢生物（02396.HK）PDGF管线直指18A赛道确定性价值
Dec 15, 2025 11:05 HKT/SGT
|
|
|
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
Dec 15, 2025 09:51 HKT/SGT
|
|
|
國資護航+技術壁壘+優質保薦 華芢生物（02396.HK）PDGF管線直指18A賽道確定性價值
Dec 15, 2025 09:28 HKT/SGT
|
|
|
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 8:30 JST
|
|
|
韓国の主要人物・金載德氏がMOVA Chain支援を表明、エコシステム発展が新段階へ
Dec 13, 2025 13:00: JST
|
|
|
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
|
|
|
京東工業登陸港交所：業績與品牌雙賦能 長期成長潛力可期
Dec 12, 2025 17:05 HKT/SGT
|
|
|
京东工业登陆港交所：业绩与品牌双赋能 长期成长潜力可期
Dec 12, 2025 17:04 HKT/SGT
|
|
|
京東工業配售結果出爐：MRO龍頭實力領跑 全鏈條數智化解決方案釋放長期價值
Dec 12, 2025 17:00 HKT/SGT
|
|
|
京东工业配售结果出炉：MRO龙头实力领跑 全链条数智化解决方案释放长期价值
Dec 12, 2025 17:00 HKT/SGT
|
|
|
全鏈條服務+業績高增長彰顯實力 京東工業港交所上市釋放長期價值
Dec 12, 2025 15:54 HKT/SGT
|
|
|
全链条服务+业绩高增长彰显实力 京东工业港交所上市释放长期价值
Dec 12, 2025 15:54 HKT/SGT
|
|
|
首隻山水實景表演概念股 印象大紅袍啟動香港公開募股
Dec 12, 2025 15:01 HKT/SGT
|
|
|
首只山水实景表演概念股 印象大红袍启动香港公开募股
Dec 12, 2025 15:00 HKT/SGT
|
|
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
